Transfusion Evidence Library

1. Carbetocin versus oxytocin for prevention of post-partum haemorrhage at caesarean section in the United Kingdom: an economic impact analysis

van der Nelson HA, Draycott T, Siassakos D, Yau CW, Hatswell AJ

European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2017;210:286-291.

Abstract

OBJECTIVE To determine the economic impact of the introduction of carbetocin for the prevention of postpartum haemorrhage (PPH) at caesarean section, compared to oxytocin. STUDY DESIGN The model is a decision tree conducted from a UK National Health Service perspective. 1500 caesarean sections (both elective and emergency) were modelled over a 12 month period. Efficacy data was taken from a published Cochrane meta-analysis, and costs from NHS Reference costs, the British National Formulary and the NHS electronic Medicines Information Tool. A combination of hospital audit data and expert input from an advisory board of clinicians was used to inform resource use estimates. The main outcome measures were the incidence of PPH and total cost over a one year time horizon, as a result of using carbetocin compared to oxytocin for prevention of PPH at caesarean section. RESULTS The use of carbetocin compared to oxytocin for prevention of PPH at caesarean section was associated with a reduction of 30 (88 vs 58) PPH events (>500ml blood loss), and a cost saving of pound27,518. In probabilistic sensitivity analysis, carbetocin had a 91.5% probability of producing better outcomes, and a 69.4% chance of being dominant (both cheaper and more effective) compared to oxytocin. CONCLUSION At list price, the introduction of carbetocin appears to provide improved clinical outcomes along with cost savings, though this is subject to uncertainty regarding the underlying data in efficacy, resource use, and cost.

0 ⋅ Show comments

2. Economic evaluation of fibrin sealant patch: a proposal to assess the economic value in hemostasis and as a surgical sealant

Colombo GL, Caruggi M, Ottolini C, Di Matteo S, Valentino MC, Bruno GM

Value in Health. 2015;18((7)):A533.

0 ⋅ Show comments

3. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling

Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, Joshi AV

Current Medical Research and Opinion. 2008;24((3):):753-768.

Taylor & Francis

0 ⋅ Show comments

4. The clinical and cost effectiveness of epoetin alfa before orthopedic surgery in patients with mild anemia

Craig J, Brown H, Eastgate J, Macpherson K, Wilson S

Transfusion Alternatives in Transfusion Medicine. 2008;10((Suppl 1):):44. Abstract No. P68.

0 ⋅ Show comments

5. Two years budget impact of epoetin alfa and autologous blood donation to avoid allogeneic transfusion in patients undergoing hip or knee orthopedic major surgery, from a major hospital perspective

Gomez-Barrera M, Izuel-Rami M, Garcia-Erce JA, Mendaza M, Rabanaque MJ

Transfusion Alternatives in Transfusion Medicine. 2006;8((1s):):79. Abstract No. P51.

0 ⋅ Show comments

6. Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery

van Hulst M, Bilgin YM, van de Watering LM, de Vries R, van Oers MH, Brand A, Postma MJ

Transfusion Medicine. 2005;15((3):):209-17.

Abstract

Cost-effectiveness of leucodepleted erythrocytes (LD) over buffy-coat-depleted packed cells (PC) is estimated from the primary dataset of a recently reported randomized clinical trial involving valve surgery (+/-CABG) patients. Data on the patient level of 474 adult patients who were randomized double-blind to LD or PC were used in order to calculate the healthcare costs and longevity per patient. The incremental cost-effectiveness ratio (ICER) in net costs per life-year gained was established from the healthcare perspective. Bootstrapping and cost-effectiveness acceptability curves were used in order to determine the confidence interval (CI) of the ICER. The longevity of patients in the PC and LD group was 10.6 and 11.4 years, respectively. Relative to PC, LD yielded an estimated 0.8 (95% CI = -0.27 to 1.84) life-year in the baseline. Adjusted for age and sex differences, health gains for LD are 0.4 life-year gained (95% CI = -0.67 to 1.44). Healthcare costs per patient averaged 10163 US dollars per patient in the PC group and 9949 US dollars in the LD group. Average cost-savings were 214 US dollars (95% CI = -1536 to 1964) per patient. Acceptability curves constructed from bootstrap simulations showed a probability of being cost-saving of 59% for universal leucodepletion from the healthcare perspective. The probability of adopting leucodepletion regardless of the costs reaches 92.7%. LD in patients receiving four or more transfusions showed the highest cost-savings and health gains. Leucodepletion of erythrocytes is a cost-saving strategy in cardiac valve (+/-CABG) patients. However, probablistic analysis failed to show a significant difference with buffy-coat-depleted PC.

0 ⋅ Show comments

7. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery

Coyle D, Lee KM, Fergusson DA, Laupacis A

Pharmacoeconomics. 2000;18((2):):161-71.